ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO078

Effects of Low Hemoglobin Levels on the Development of Contrast-Induced AKI

Session Information

Category: Acute Kidney Injury

  • 101 AKI: Epidemiology‚ Risk Factors‚ and Prevention

Authors

  • Zhou, Fangfang, HwaMei Hospital, University Of Chinese Academy of Science, Ningbo, China
  • Lu, Yi, HwaMei Hospital, University Of Chinese Academy of Science, Ningbo, China
  • Xu, Youjun, HwaMei Hospital, University Of Chinese Academy of Science, Ningbo, China
  • Zhang, Shuzhen, HwaMei Hospital, University Of Chinese Academy of Science, Ningbo, China
  • Luo, Qun, HwaMei Hospital, University Of Chinese Academy of Science, Ningbo, China
Background

The aim of this study was to evaluate the relationship between low hemoglobin levels and the development of CI-AKI in patients undergoing angiographic intervention, coronary angiography (CAG) and/or percutaneous coronary intervention (PCI).

Methods

Patients aged ≥18 years who underwent elective angiographic intervention and CAG and/or PCI in the Department of Cardiology and Vascular Surgery of our hospital from January 2016 to December 2020. According to KDIGO criteria of AKI, patients were divided into: (1) AKI group: AKI occurred after CM was used; (2) Non-AKI group: no AKI occurred after CM was used. The baseline characteristics of patients, preoperative use of medicines, laboratory test indicators (eGFR was calculated using EPI formula) and other parameters of each patient were collected retrospectively. SPSS 22.0 software was used for statistical analysis.

Results

A total of 2230 patients were included in the study. The hemoglobin (g/L) in patients with CI-AKI was 117.50 (108.00,133.00), significantly lower than that in patients without CI-AKI (130.00 (118.00,142.00) (P<0.001). The low hemoglobin group was assigned according to hemoglobin level (male, <120 g/L; female, <110 g/L; N=40) and normal hemoglobin group (male 120-160g/L; female, 110-150g/L; N=80). Multivariate logistic regression analysis showed that 4.30% of patients in the normal hemoglobin group developed CI-AKI, and 10.87% of patients in the low hemoglobin group developed CI-AKI, low hemoglobin (male, <120 g/L; female,<110 g/L) was an independent protective factor for CI-AKI (OR=1.667, =0.001). The independent risk factors for CI-AKI in patients with low hemoglobin level were hyperlipidemia (OR=5.556, P=0.01) and atrial fibrillation (OR=2.703, P=0.039) and history of coronary artery disease (OR=2.833, P=0.006), use of ACEI (OR=3.521, P=0.023) and ARB (OR=2.732, P=0.011), fasting glucose increased (OR=1.186, P=0.001). For patients with normal hemoglobin level, independent risk factors for CI-AKI were increased systolic blood pressure (OR=1.015, P=0.008) and positive urine protein (OR=2.114, P=0.019), increased neutrophil/lymphocyte ratio (OR=1.079, P=0.017), history of chronic kidney disease (OR=5.102, P<0.0001), use of low molecular weight heparin (OR=2.222, P=0.002) and spironolactone (OR=2.564, P=0.033).

Conclusion

Low hemoglobin level is an independent risk factor for CI-AKI.

Funding

  • Government Support – Non-U.S.